Details of the Drug

General Information of Drug (ID: DMMZXIW)

Drug Name
Rabeprazole
Synonyms
Dexrabeprazole; Eraloc; Rebeprazole sodium; CL23619; LY307640; Aciphex (TN); Eraloc (TN); Pariet (TN); Rabeprazole (INN); Rabeprazole [BAN:INN]; Rabeprazole [INN:BAN]; Rablet (TN); 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole; 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1], [2]
Therapeutic Class
Antiulcer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 359.4
Topological Polar Surface Area (xlogp) 1.9
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 52% [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 4 mL/min/kg [5]
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 - 2 hours (in plasma) [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.5 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.037% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.22 L/kg [5]
Chemical Identifiers
Formula
C18H21N3O3S
IUPAC Name
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
Canonical SMILES
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
InChI
InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
InChIKey
YREYEVIYCVEVJK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5029
ChEBI ID
CHEBI:8768
CAS Number
117976-89-3
DrugBank ID
DB01129
TTD ID
D0KL4J
VARIDT ID
DR01195
INTEDE ID
DR1387
ACDINA ID
D00578

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric H(+)/K(+) ATPase alpha (ATP4A) TTF1QVM ATP4A_HUMAN Inhibitor [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Bacterial infection
ICD Disease Classification 1A00-1C4Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastric H(+)/K(+) ATPase alpha (ATP4A) DTT ATP4A 1.42E-02 -0.15 -1.5
Breast cancer resistance protein (ABCG2) DTP BCRP 3.39E-04 -4.15E+00 -3.65E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.51E-02 1.95E-01 1.20E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.90E-02 -3.45E-01 -1.49E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rabeprazole
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Kanamycin DM2DMPO Moderate Increased risk of hypomagnesemia by the combination of Rabeprazole and Kanamycin. Bacterial infection [1A00-1C4Z] [43]
Cefpodoxime DMJUNY5 Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [44]
Bacampicillin DMP54C7 Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [44]
Coadministration of a Drug Treating the Disease Different from Rabeprazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Accelerated clearance of Rabeprazole due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [45]
Paromomycin DM1AGXN Moderate Increased risk of hypomagnesemia by the combination of Rabeprazole and Paromomycin. Amoebiasis [1A36] [43]
Posaconazole DMUL5EW Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Posaconazole. Aspergillosis [1F20] [46]
Vismodegib DM5IXKQ Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Vismodegib. Basal cell carcinoma [2C32] [47]
Pexidartinib DMS2J0Z Major Decreased absorption of Rabeprazole due to altered gastric pH caused by Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [48]
Lapatinib DM3BH1Y Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Lapatinib. Breast cancer [2C60-2C6Y] [45]
HKI-272 DM6QOVN Major Decreased absorption of Rabeprazole due to altered gastric pH caused by HKI-272. Breast cancer [2C60-2C6Y] [47]
Bosutinib DMTI8YE Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Bosutinib. Breast cancer [2C60-2C6Y] [49]
Panitumumab DMQPD1F Moderate Increased risk of hypomagnesemia by the combination of Rabeprazole and Panitumumab. Colorectal cancer [2B91] [43]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Rabeprazole caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [50]
Stiripentol DMMSDOY Moderate Decreased metabolism of Rabeprazole caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Itraconazole DMCR1MV Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Itraconazole. Fungal infection [1F29-1F2F] [52]
GS-5885 DMSL3DX Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by GS-5885. Hepatitis virus infection [1E50-1E51] [47]
Rifapentine DMCHV4I Moderate Increased metabolism of Rabeprazole caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [53]
Fosamprenavir DM4W9B3 Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Fosamprenavir. Human immunodeficiency virus disease [1C60-1C62] [54]
Etravirine DMGV8QU Moderate Increased metabolism of Rabeprazole caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [55]
Rilpivirine DMJ0QOW Major Decreased absorption of Rabeprazole due to altered gastric pH caused by Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [56]
Raltegravir DMYURI6 Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Raltegravir. Human immunodeficiency virus disease [1C60-1C62] [57]
Iron DMAP8MV Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Iron. Iron deficiency anaemia [3A00] [58]
Brigatinib DM7W94S Moderate Increased metabolism of Rabeprazole caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
Ceritinib DMB920Z Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Ceritinib. Lung cancer [2C25] [60]
Dacomitinib DMOH8VY Major Decreased absorption of Rabeprazole due to altered gastric pH caused by Dacomitinib. Lung cancer [2C25] [45]
Selpercatinib DMZR15V Major Decreased absorption of Rabeprazole due to altered gastric pH caused by Selpercatinib. Lung cancer [2C25] [45]
Acalabrutinib DM7GCVW Major Decreased absorption of Rabeprazole due to altered gastric pH caused by Acalabrutinib. Mature B-cell lymphoma [2A85] [61]
Ponatinib DMYGJQO Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Ponatinib. Mature B-cell lymphoma [2A85] [47]
Exjade DMHPRWG Moderate Decreased metabolism of Rabeprazole caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [62]
Flibanserin DM70DTN Moderate Decreased metabolism of Rabeprazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [63]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Rabeprazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [45]
Nilotinib DM7HXWT Moderate Increased risk of hypomagnesemia by the combination of Rabeprazole and Nilotinib. Myeloproliferative neoplasm [2A20] [64]
Dasatinib DMJV2EK Major Decreased absorption of Rabeprazole due to altered gastric pH caused by Dasatinib. Myeloproliferative neoplasm [2A20] [65]
Prasugrel DM7MT6E Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Prasugrel. Myocardial infarction [BA41-BA43] [66]
Polythiazide DMCH80F Moderate Increased risk of hypomagnesemia by the combination of Rabeprazole and Polythiazide. Oedema [MG29] [43]
Abametapir DM2RX0I Moderate Decreased metabolism of Rabeprazole caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [67]
Lefamulin DME6G97 Moderate Decreased metabolism of Rabeprazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [68]
Choline salicylate DM8P137 Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Choline salicylate. Postoperative inflammation [1A00-CA43] [69]
Enzalutamide DMGL19D Moderate Increased metabolism of Rabeprazole caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [70]
Riociguat DMXBLMP Moderate Decreased absorption of Rabeprazole due to altered gastric pH caused by Riociguat. Pulmonary hypertension [BB01] [71]
Axitinib DMGVH6N Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Axitinib. Renal cell carcinoma [2C90] [72]
Salsalate DM13P4C Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Salsalate. Rheumatoid arthritis [FA20] [69]
Armodafinil DMGB035 Moderate Decreased metabolism of Rabeprazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Vandetanib DMRICNP Minor Decreased absorption of Rabeprazole due to altered gastric pH caused by Vandetanib. Solid tumour/cancer [2A00-2F9Z] [47]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Rabeprazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [73]
Plazomicin DMKMBES Moderate Increased risk of hypomagnesemia by the combination of Rabeprazole and Plazomicin. Urinary tract infection [GC08] [43]
⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Potassium chloride E00074 4873 Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Carbonic acid disodium salt E00199 10340 Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 34 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rabeprazole 20 mg tablet 20 mg Delayed Release Oral Tablet Oral
Rabeprazole 10 mg granules 10 mg Oral Granules Oral
Rabeprazole 5 mg granules 5 mg Oral Granules Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7290).
2 An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
8 Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:11-6.
9 Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
10 Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
21 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
22 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
23 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
24 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
25 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
26 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
27 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
28 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
29 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
30 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
31 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
32 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
33 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
34 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
35 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
36 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
37 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
38 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
39 Clinical pipeline report, company report or official report of Takeda (2009).
40 Clinical pipeline report, company report or official report of AstraZeneca (2009).
41 Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
43 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
44 Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
45 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
46 Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
47 Cerner Multum, Inc. "Australian Product Information.".
48 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
49 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Cerner Multum, Inc. "Canadian Product Information.".
51 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
52 Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
53 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
54 Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
55 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
56 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
57 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
58 Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
59 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
60 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
61 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
62 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
64 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
65 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
66 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
67 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
68 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
69 Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
70 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
71 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
72 Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.